Kukje Pharma Co., Ltd.
Founded in 1959, Kukje Pharma produces prescription and OTC drugs including Cuallon eye drops, Cholencina capsules, and Retium tablets.
As of 2026-10-11, Kukje Pharma Co., Ltd. has 1 Korean MFDS device approval, 264 Korean MFDS drug approvals, 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1959 and listed on KOSPI in 1975, Kukje Pharma is a pharmaceutical company. It produces prescription and OTC drugs including Cuallon eye drops, Cholencina soft capsules, Ezeroba tablets, Identgelt injection, and Retium tablets at its manufacturing/research facility in Ansan, Gyeonggi Province, selling through pharmacies, clinics, hospitals, and wholesalers. In its 68th fiscal year (2025), consolidated revenue rose about 12.2% year-on-year to KRW 175,496 million and separate-entity revenue rose about 13.6% to KRW 170,542 million, while the company had two new drug research programs and three improved new drug research programs underway.
Products & technology
- Cuallon Eye Drops
- Cholencina Soft Cap.
- Ezeroba Tab.
- Identgelt Injection
- Retium Tab.
Regulatory approvals
data.go.kr264 Korean MFDS drug approvals · 1978–2026 / 1 Korean MFDS device approvals · 2014
- MFDS drugKukje Pitavastatin OD tab. 2mg2026-07-30Drug · Prescription · Approval202602222
- MFDS drugKukje Pitavastatin OD tab. 4mg2026-07-30Drug · Prescription · Approval202602223
- MFDS drugkukje vonoprazan Tab 10mg2026-07-08Drug · Prescription · Approval202601982
- MFDS drugkukje vonoprazan Tab 20mg2026-07-08Drug · Prescription · Approval202601983
- MFDS drugPelofen Tab(Pelubiprofen(micronized))2026-06-30Drug · Prescription · Approval202601906
- MFDS drugEXDUO plus tab. 2.5/80/1.25mg2026-05-06Drug · Prescription · Approval202601336
- MFDS drugEXDUO plus tab. 2.5/160/2.5mg2026-05-06Drug · Prescription · Approval202601337
- MFDS drugEXDUO plus tab. 2.5/160/1.25mg2026-05-06Drug · Prescription · Approval202601338
- MFDS drugRosudipine Tab 5/5mg2026-04-09Drug · Prescription · Approval202601021
- MFDS drugRosudipine Tab 10/5mg2026-04-09Drug · Prescription · Approval202601022
- MFDS drugRosudipine Tab 20/5mg2026-04-09Drug · Prescription · Approval202601023
- MFDS drugEXDUO 2.5/80mg2026-02-25Drug · Prescription · Approval202600574
Show 68 more
- MFDS drugKUKJE GINKGO LEAF DRIDED EXTRACT 120mg2025-10-17Drug · OTC · Notification202502694
- MFDS drugPiperatam Inj, 4.5g(Piperacillin sodium. Tazobactam sodium)2025-10-02Drug · Prescription · Approval202502623
- MFDS drugGLIANCE DUO 12.5/850mg2025-07-08Drug · Prescription · Approval202501691
- MFDS drugGLIANCE DUO 12.5/500mg2025-07-08Drug · Prescription · Approval202501692
- MFDS drugGLIANCE DUO 12.5/1000mg2025-04-17Drug · Prescription · Approval202500926
- MFDS drugLanope Eye drops2024-12-20Drug · Prescription · Approval202403034
- MFDS drugTrazosin tab.2024-11-21Drug · Prescription · Approval202402741
- MFDS drugDikozin tab. 240mg2024-08-14Drug · OTC · Notification202401980
- MFDS drugLEVOKACIN 1.5%(Levofloxacin hydrate)2024-05-10Drug · Prescription · Approval202401153
- MFDS drugNIGOLINE tab.2024-02-29Drug · Prescription · Approval202400425
- MFDS drugJanudi-M Tab.50/1000mg2023-03-13Drug · Prescription · Approval202300851
- MFDS drugJanudi-M Tab.50/500mg2023-03-13Drug · Prescription · Approval202300852
- MFDS drugJanudi-M Tab.50/850mg2023-03-13Drug · Prescription · Approval202300853
- MFDS drugJanudi-M XR Tab.100/1000mg2023-02-17Drug · Prescription · Approval202300599
- MFDS drugJanudi-M XR Tab.50/1000mg2023-02-17Drug · Prescription · Approval202300600
- MFDS drugJanudi-M XR Tab.50/500mg2023-02-17Drug · Prescription · Approval202300601
- MFDS drugFORXIDI-M XR Tab. 5/500mg2023-01-17Drug · Prescription · Approval202300273
- MFDS drugFORXIDI-M XR Tab. 10/500mg2023-01-17Drug · Prescription · Approval202300274
- MFDS drugTABEON SR tab.2022-12-21Drug · Prescription · Approval202204558
- MFDS drugForxiDCM SR Tab. 5/500mg2022-11-10Drug · Prescription · Approval202204070
- MFDS drugForxiDCM SR Tab. 10/500mgRevoked2022-11-10Drug · Prescription · Approval202204069
- MFDS drugONCEEYE Eye Drops 1%(Carboxymethylcellulose sodium)(disposable)2022-06-30Drug · OTC · Notification202202694
- MFDS drugREBAEYE 2%(Rebamipide)2022-06-16Drug · Prescription · Approval202202521
- MFDS drugJOINTOFA 5mg(Tofacitinib citrate)2022-04-20Drug · Prescription · Approval202201620
- MFDS drugGLIANCE DUO 5/500mg2022-04-04Drug · Prescription · Approval202201389
- MFDS drugGLIANCE DUO 5/850mg2022-04-04Drug · Prescription · Approval202201390
- MFDS drugGLIANCE DUO 5/1000mg2022-04-04Drug · Prescription · Approval202201391
- MFDS drugTENELDI-M 20/1000mg2022-04-04Drug · Prescription · Approval202201409
- MFDS drugTENELDI-M 10/750mg2022-04-04Drug · Prescription · Approval202201410
- MFDS drugTENELDI-M 10/500mg2022-04-04Drug · Prescription · Approval202201411
- MFDS drugBrilelor60mg(Ticagrelor)2022-02-04Drug · Prescription · Approval202200550
- MFDS drugBROEYE(Bromfenac sodium sesquihydrate)2022-01-06Drug · Prescription · Approval202200106
- MFDS drugFORXIVIS 10/100mg2022-01-04Drug · Prescription · Approval202200043
- MFDS drugKUKJE HYAL(Sodium Hyaluronate)2021-11-10Drug · Prescription · Notification202107382
- MFDS drugFORXIDI-M 5/1000mg2021-10-29Drug · Prescription · Approval202107223
- MFDS drugFORXIDI-M 10/1000mg2021-10-29Drug · Prescription · Approval202107224
- MFDS drugKUKJE RIVAROXABAN 20mgRevoked2021-04-23Drug · Prescription · Approval202103352
- MFDS drugKUKJE RIVAROXABAN 15mgRevoked2021-04-23Drug · Prescription · Approval202103353
- MFDS drugKUKJE RIVAROXABAN 10mgRevoked2021-04-23Drug · Prescription · Approval202103354
- MFDS drugSITAVIS-S 100mg(Sitagliptin hydrochloride monohydrate)2021-04-06Drug · Prescription · Approval202102956
- MFDS drugSITAVIS-S 25mg(Sitagliptin hydrochloride monohydrate)2021-04-06Drug · Prescription · Approval202102957
- MFDS drugSITAVIS-S 50mg(Sitagliptin hydrochloride monohydrate)2021-04-06Drug · Prescription · Approval202102958
- MFDS drugGLIANCE 10mg(Empagliflozin)2021-02-24Drug · Prescription · Approval202101825
- MFDS drugGLIANCE 25mg(Empagliflozin)2021-02-24Drug · Prescription · Approval202101826
- MFDS drugAPEZET 10/20mg2021-01-08Drug · Prescription · Approval202100231
- MFDS drugAPEZET 10/10mg2021-01-08Drug · Prescription · Approval202100232
- MFDS drugAPEZET 10/40mgRevoked2021-01-08Drug · Prescription · Approval202100230
- MFDS drugCOLENSINA(Choline alfoscerate)2020-11-30Drug · Prescription · Approval202008371
- MFDS drugDITOREN(Cefditoren pivoxil)2020-11-25Drug · Prescription · Approval202008182
- MFDS drugTENELDI 20mg(Teneligliptin hydrochloride hydrate)2020-11-05Drug · Prescription · Approval202007626
- MFDS drugKUKJE GINKGO LEAF EXTRACTRevoked2020-09-16Drug · OTC · Notification202006399
- MFDS drugFORXIDI 10mg(Dapagliflozin anhydrous lactose mixture)2020-07-23Drug · Prescription · Approval202005319
- MFDS drugFORXIDI 5mg(Dapagliflozin anhydrous lactose mixture)Revoked2020-07-23Drug · Prescription · Approval202005318
- MFDS drugTHY-N(Thymosin α1)Revoked2020-05-22Drug · Prescription · Approval202003767
- MFDS drugOMECIN(Omega-3-acid ethyl esters 90)2020-05-19Drug · Prescription · Approval202003634
- MFDS drugKUKJE LEVOFLOXACIN HYDRATE(For export)2020-05-06Drug · Prescription · Approval202003289
- MFDS drugALLEPATADINE 0.7%(Olopatadine hydrochloride)2020-04-29Drug · Prescription · Approval202003227
- MFDS drugUTANAL 0.4mg(Tamsulosin hydrochloride)2020-04-22Drug · Prescription · Approval202002875
- MFDS drugKUKJE MOSARIDE 15mg(Mosapride citrate hydrate)2020-04-22Drug · Prescription · Approval202002901
- MFDS drugKUKJE MOXIFLOXACIN HYDROCHLORIDE(For export)2020-04-09Drug · Prescription · Approval202002505
- MFDS drugNEOBENZOLE(Albendazole)Revoked2020-04-02Drug · OTC · Notification202002321
- MFDS drugKUKJE LINCOMYCIN HYDROCHLORIDE HYDRATE 600mgRevoked2020-03-27Drug · Prescription · Notification202002164
- MFDS drugEpinawon Tab.2020-03-18Drug · Prescription · Approval202001881
- MFDS drugPOLEMAC(Polaprezinc)Revoked2020-03-11Drug · Prescription · Approval202001698
- MFDS drugPAFECTON PLUS2020-03-09Drug · Prescription · Approval202001616
- MFDS drugGLAVIS 1000mg(Metformin hydrochloride)2020-03-05Drug · Prescription · Approval202001548
- MFDS drugDIQUEYE(Diquafosol sodium)(Disposable)2020-02-21Drug · Prescription · Approval202001277
- MFDS drugNAFUDI(Lafutidine)2019-12-24Drug · Prescription · Approval201908602
Showing the 80 most recent of 265 records.
Clinical trials
data.go.kr46 MFDS clinical trial authorisations · 2012–2025 (Bioequivalence 29 · Phase 1 11 · Phase 3 3 · Phase 2a 1 · Phase 2 1)
- BioequivalenceKJG25-012025-09-01
2 trial sites
- BioequivalenceKJD24-012024-06-04
2 trial sites
- BioequivalenceKJD23-012024-01-22
2 trial sites
- Phase 2aTFC-0032023-05-25
2 trial sites
- BioequivalenceKJD23-012023-05-24
2 trial sites
- Phase 1KJD22-032023-01-16
1 trial site
- Phase 1KJD22-032023-01-02
1 trial site
- BioequivalenceKJD22-022022-09-29
2 trial sites
- BioequivalenceKJD21-042021-09-14
2 trial sites
- BioequivalenceKJD21-042021-09-13
2 trial sites
- BioequivalenceKJD21-032021-06-17
2 trial sites
- BioequivalenceKJD20-032021-03-12
2 trial sites
Show 34 more
- BioequivalenceKJD20-032021-03-12
2 trial sites
- BioequivalenceKJD20-042020-12-21
2 trial sites
- BioequivalenceKJD20-052020-09-10
2 trial sites
- Phase 2HCS-0012020-07-10
- BioequivalenceKJD20-022020-06-19
2 trial sites
- BioequivalenceKJD20-012020-05-25
2 trial sites
- Phase 3TFC-0032020-03-17
27 trial sites
- BioequivalenceKJD19-022020-02-04
2 trial sites
- BioequivalenceKJD19-062019-11-06
2 trial sites
- Bioequivalence국제로잘탄플러스에프정2019-07-16
2 trial sites
- Phase 2b/3KSR-0012019-07-10
16 trial sites
- Bioequivalence유타날캡슐0.4밀리그램(탐스로신염산염)2019-04-19
2 trial sites
- Bioequivalence디토렌세립(세프디토렌피복실)2019-04-16
2 trial sites
- Bioequivalence유타날캡슐0.4밀리그램(탐스로신염산염)2019-04-16
2 trial sites
- Bioequivalence글라비스정1000밀리그램(메트포르민염산염)2019-03-15
2 trial sites
- BioequivalenceKJD19-012019-01-22
2 trial sites
- Phase 1KSR-0012018-09-17
1 trial site
- Bioequivalence안티그렐서방정(사르포그렐레이트염산염)2018-03-23
2 trial sites
- Bioequivalence레티움정(도베실산칼슘수화물)2017-12-28
2 trial sites
- Phase 1HCS-0012017-10-16
1 trial site
- Bioequivalence트라디엠듀오정 2.5/1000mg2017-01-18
2 trial sites
- Phase 3KJCS-0052016-12-14
5 trial sites
- Bioequivalence트라디엠정 5mg(리나글립틴)2016-11-21
2 trial sites
- Bioequivalence콜렌시아정(콜린알포세레이트)2016-10-26
2 trial sites
- Phase 1TFC-0032016-06-29
1 trial site
- Bioequivalence에릭손정(에페리손염산염)2016-04-27
2 trial sites
- Phase 3INT-21502015-11-09
13 trial sites
- Phase 1TFC-0032015-11-06
1 trial site
- Bioequivalence니코놉서방정(부프로피온염산염)2015-10-14
2 trial sites
- Phase 1INT-21502015-03-25
1 trial site
- Phase 1INT-21502014-11-20
1 trial site
- Phase 1맥시그라구강붕해정50밀리그램(실데나필시트르산염)2012-05-16
1 trial site
- Phase 1맥시그라구강붕해정50밀리그램(실데나필시트르산염)2012-04-23
1 trial site
- Phase 1맥시그라구강붕해정50밀리그램(실데나필시트르산염)2012-04-20
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 3 · Recruiting · 2025-12 · NCT07662759
Phase 2 · Unknown · 2024-02 · NCT06177678
Phase 2/3 · Completed · 2020-02 · NCT05017844
Phase 1 · Completed · 2018-12 · NCT05017870
Phase 1 · Unknown · 2017-11 · NCT03509831
Phase 1 · Completed · 2016-12 · NCT02967614
R&D and key agreements
Source: DART corporate disclosure신약 연구(2건) · Two new drug programs underway as of December 31, 2025; specific names/indications not disclosed in the source
개량신약 연구(3건) · Three improved new drug programs underway as of December 31, 2025; specific names/indications not disclosed in the source
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits.
Molecules (Basel, Switzerland) · 2020-02 · Choi EJ, Choi GW, Kim JH 외 6
Patents
KIPRIS · applicant-matchedRegistered · 2023-05 · Application 1020230064410
Published · 2022-01 · Application 1020220013541
PCT · Published · 2020-10 · Application PCT/KR2020/014947
Registered · 2020-10 · Application 1020200142244
US · Registered · 2020-08 · Application 17638707
EP · Published · 2020-08 · Application 20856041.7
PCT · Published · 2020-08 · Application PCT/KR2020/011372
Registered · 2020-08 · Application 1020200107675
Registered · 2019-02 · Application 1020190023251
Registered · 2018-05 · Application 1020180055622
Show 33 more patents
PCT · Published · 2018-03 · Application PCT/KR2018/002786
CN · Published · 2017-12 · Application 201780078021.7
US · Registered · 2017-12 · Application 16469969
EP · Registered · 2017-12 · Application 17882056.9
PCT · Published · 2017-12 · Application PCT/KR2017/014798
JP · Registered · 2017-12 · Application 31554459
PCT · Published · 2017-09 · Application PCT/KR2017/009693
Registered · 2017-03 · Application 1020170033389
Registered · 2016-12 · Application 1020160172784
Registered · 2016-09 · Application 1020160114137
Registered · 2015-12 · Application 1020150191020
Registered · 2015-08 · Application 1020150117785
Registered · 2015-07 · Application 1020150107237
Withdrawn · 2010-12 · Application 1020100123295
Expired · 2008-09 · Application 1020080090904
Expired · 2008-09 · Application 1020080090908
Expired · 2008-03 · Application 1020080028691
Expired · 2007-11 · Application 1020070120038
Expired · 2000-11 · Application 1020000071824
Expired · 2000-03 · Application 1020000015512
Expired · 1998-11 · Application 1019980049925
Expired · 1998-06 · Application 1019980022890
Rejected · 1997-04 · Application 1019970012490
Expired · 1996-11 · Application 1019960053527
Rejected · 1996-11 · Application 1019960053528
Rejected · 1996-11 · Application 1019960053526
Expired · 1995-12 · Application 1019950055058
Rejected · 1995-12 · Application 1019950055057
Expired · 1995-11 · Application 1019950045662
Expired · 1995-11 · Application 1019950045661
Expired · 1989-12 · Application 1019890019150
Withdrawn · 1989-10 · Application 1019890014682
Expired · 1966-06 · Application 2019660001571
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive7
- OpenAIOAI-SearchBot68
- PerplexityPerplexityBot4
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Kukje Pharma Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed medical device company producing auto refractors, auto lensmeters, and other ophthalmic equipment.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition